Skip to primary navigation Skip to main content
Buffalo Local Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Atara Biotherap (NQ: ATRA)
34.97 USD  -0.80 (-2.24%)
Official Closing Price  /  Updated: 4:43 PM EDT, Oct 19, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 369,800
Open 35.88
Bid (Size) 34.97 (32)
Ask (Size) 34.99 (17)
Prev. Close 35.77
Today's Range 34.38 - 36.85
52wk Range 12.65 - 54.45
Shares Outstanding 43,949,486
Dividend Yield N/A
Performance
YTD
+93.20%
+93.20%
1 Month
-12.58%
-12.58%
3 Month
-10.79%
-10.79%
6 Month
-11.47%
-11.47%
1 Year
+143.69%
+143.69%
Top News
More News
Report: Exploring Fundamental Drivers Behind Monroe Capital, Anavex Life Sciences, Haynes International, Atara Biotherapeutics, Lands' End, and Envestnet — New Horizons, Emerging Trends, and Upcoming
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Monroe Capital Corporation... Read More
from GlobeNewswire News Releases
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, today... Read More
from GlobeNewswire News Releases
More News
Read More
Atara Biotherapeutics Appoints Cancer Research and Clinical Development Veteran, Roy Baynes, to its Board of Directors
from GlobeNewswire News Releases
Atara Biotherapeutics and Moffitt Cancer Center Announce Strategic Collaboration to Develop Next-Generation CAR T Immunotherapies
from GlobeNewswire News Releases
Atara Biotherapeutics to Participate at Two Upcoming Conferences
from GlobeNewswire News Releases
Analysis: Positioning to Benefit within Quanex Building Products, Molecular Templates, Atara Biotherapeutics, Forward Industries, Apollo Endosurgery, and Myomo — Research Highlights Growth, Revenue, a
from GlobeNewswire News Releases
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
from GlobeNewswire News Releases
Atara Biotherapeutics Announces Second Quarter 2018 Financial Results and Recent Operational Progress
from GlobeNewswire News Releases
Atara Biotherapeutics to Participate in the Canaccord Genuity 38th Annual Growth Conference
from GlobeNewswire News Releases
Peek Under The Hood: JKJ Has 19% Upside
category ETFs
from ETF Channel
Atara Biotherapeutics Opens State-of-the-Art Operations and Manufacturing Facility to Support Robust Off-the-Shelf T-Cell Immunotherapy Pipeline
from GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.